Drug Trial Radar · NCT05886920
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Jul 10, 2023
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- D3 Bio (Wuxi) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
Conditions
- Advanced Solid Tumors With MAPK Pathway Mutations
Interventions
D3S-002Drug
Oral Tablet
D3S-001Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: First dose until 30 days after the last dose (or specified in the protocol)
- Maximum tolerated dose (MTD) based on Dose limiting toxicities (DLTs)Time frame: First dose up to 24 months
- Recommended Phase 2 dose (RP2D)Time frame: First dose up to 24 months
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
D3 Bio Investigative Site
Detroit, Michigan · Recruiting
D3 Bio Investigative Site
New York, New York · Completed
D3 Bio Investigative Site
Nashville, Tennessee · Recruiting
D3 Bio Investigative Site
Houston, Texas · Recruiting
D3 Bio Investigative Site
Blacktown, New South Wales, Australia · Completed
D3 Bio Investigative Site
Macquarie Park, New South Wales, Australia · Recruiting
D3 Bio Investigative Site
Bedford Park, South Australia, Australia · Completed
D3 Bio Investigative Site
Melbourne, Victoria, Australia · Recruiting
D3 Bio Investigative Site
Nedlands, Western Australia, Australia · Completed
D3 Bio Investigative Site
Beijing, Beijing Municipality, China · Recruiting
D3 Bio Investigative Site
Guangzhou, Guangdong, China · Recruiting
D3 Bio Investigative Site
Harbin, Heilong Jiang, China · Suspended
D3 Bio Investigative Site
Wuhan, Hubei, China · Recruiting
D3 Bio Investigative Site
Shanghai, Shanghai Municipality, China · Recruiting
D3 Bio Investigative Site
Shanghai, Shanghai Municipality, China · Active not recruiting
D3 Bio Investigative Site
Chengdu, Sichuan, China · Recruiting
D3 Bio Investigative Site
Hangzhou, Zhejiang, China · Recruiting
D3 Bio Investigative Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.